Nasdaq 100 Stocks SEC Filings — March 06, 2026

06-03-2026

FIRST Community Bankshares Inc. reported net income of $48.8 million for 2025, down 5.45% from $51.6 million in 2024, with ROA declining to 1.52% from 1.60% and ROE to 9.64% from 10.03%; net interest income FTE fell slightly to $125.1 million while NIM remained nearly flat at 4.42% (down 0.02 percentage points). However, noninterest income rose 8.88% to an unspecified amount driven by service charges, credit quality improved with non-performing loans at 0.61% (down 0.22 percentage points) and lower net charge-offs, and adjusted net income declined modestly by 2.34% to $51.1 million. Noninterest expenses increased 8.01% due to higher salaries, merger costs for the Hometown acquisition (completed January 23, 2026), and other expenses.

• ·Merger-related expenses of $2.91 million in 2025 associated with Hometown acquisition completed January 23, 2026.
• ·Salaries and employee benefits increased $4.73 million YoY.
• ·Book value per share $27.30 on Dec 31, 2025, down $1.43 from 2024 due to special dividends totaling $3.07 per share.
• ·Average loans $2.35B in 2025 vs $2.48B in 2024.
• ·Loan-to-deposit ratio 88.81% on Dec 31, 2025.
• ·Return on average tangible common equity 13.92% for 2025.

06-03-2026

On March 4, 2026, Alphabet's Leadership Development, Inclusion and Compensation Committee approved a new triennial equity compensation package for CEO Sundar Pichai, recognizing his strong performance, including unchanged on-target values for $126M in PSUs and $84M in GSUs from the 2022 award, plus $130M target Waymo BPUs and $45M target Wing BPUs tied to Other Bets performance. However, his annual salary remains flat at $2M (unchanged since 2020) with no eligibility for an annual bonus. All awards are performance-based with potential 0-200% vesting ranges relative to targets, subject to TSR, unit value growth, and continued employment.

• ·PSUs vest based on Alphabet TSR vs. S&P 100 over 2026-2027 (tranche 1) and 2026-2028 (tranche 2).
• ·GSUs vest 1/12th on March 25, 2026, then 1/36th monthly through January 1, 2029.
• ·Waymo/Wing BPUs vest after 3-year period based on per-unit value increase (0-200%), settling in Common Units.
• ·Award agreements to be filed in 10-Q for quarter ending March 31, 2026.
• ·Upon death, unvested GSUs accelerate; performance equity vests at target.

06-03-2026

Canadian Imperial Bank of Commerce (CIBC) filed a Form F-3 registration statement with the SEC on March 5, 2026, to register up to $20 billion in senior debt securities for potential sale on a delayed or continuous basis pursuant to Rule 415, with specific terms to be detailed in future prospectus supplements. The filing highlights risks including geopolitical tensions, regulatory changes, and cyber threats, but provides no current financial performance metrics or period-over-period comparisons. Securities are not insured by CDIC or FDIC and may be subject to bail-in conversion under Canadian law.

• ·Registrant address: 81 Bay Street, CIBC Square, Toronto, Ontario, Canada M5J 0E7
• ·U.S. agent for service: 300 Madison Avenue, 6th Floor, New York, New York 10017
• ·Securities may be bail-inable under subsection 39.2(2.3) of the CDIC Act

06-03-2026

Nuveen AMT-Free Quality Municipal Income Fund extended the final mandatory redemption date of its Series 4 Variable Rate Demand Preferred Shares, aggregate liquidation preference $489.5M, from September 11, 2026, to September 11, 2056, effective March 5, 2026. The preferred shares feature weekly dividends set by a remarketing agent with a liquidity provision and are senior to common shares in liquidation and dividends. No performance declines or flat metrics were reported in this disclosure.

• ·Fund's fiscal year end is October 31.
• ·Series 4 shares are not registered under the Securities Act of 1933 and cannot be offered or sold without exemption.

06-03-2026

Altimmune, Inc. reported revenues of $41K for the year ended December 31, 2025, up 105% YoY from $20K, driven by minimal grant or collaboration income, while R&D expenses declined 19% to $66.4M, contributing to a reduced net loss of $88.1M (7% improvement) versus $95.1M in 2024. However, G&A expenses rose 34% to $28.1M, total cash increased to $43.8M supported by $207M in financing inflows despite $132M investing outflows and $68M operating cash burn.

• ·Shares outstanding increased to 110.9M from 72.4M YoY.
• ·Term loan noncurrent liability of $34.3M as of Dec 31, 2025 (none in 2024).
• ·Key audit matter on accrued R&D expenses ($6.1M) and prepaid R&D ($3.0M) as of Dec 31, 2025.
• ·Filing date: March 06, 2026.

06-03-2026

Immuneering reported 64% overall survival at 12 months in its ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients (N=34), well above the 35% GnP standard of care benchmark, with a favorable tolerability profile. Cash, cash equivalents, and marketable securities stood at $217M as of December 31, 2025, up significantly from $36.1M at year-end 2024, providing runway into 2029; R&D expenses declined 37% YoY to $9.3M in Q4 and 13% to $42M for FY2025. However, G&A expenses rose 22% YoY to $4.5M in Q4 and 8% to $17.3M for FY2025, contributing to a FY2025 net loss of $56M ($1.27/share), improved from $61M ($2.04/share) in FY2024 but still reflecting ongoing unprofitability.

• ·On track for expanded pancreatic cancer cohort data readout in 1H 2026.
• ·Dose first patient in Phase 3 MAPKeeper 301 trial mid-2026.
• ·Dosing in Phase 2 atebimetinib + Libtayo® NSCLC trial to begin 2H 2026.
• ·Added to Nasdaq Biotechnology Index on Dec 22, 2025.
• ·13.4 months median follow-up in Phase 2a trial as of Dec 15, 2025 data cutoff.

06-03-2026

Adial Pharmaceuticals reported FY2025 financial results with cash and equivalents at $5.9M (up from $3.8M in FY2024), a reduced net loss of $8.0M (vs. $13.2M prior year, improved ~39%), R&D expenses down 19% ($609K decrease), but G&A expenses up 2% ($125K increase). The company advanced AD04 regulatory progress including positive FDA feedback and EOP2 meeting, expanded IP with patents through 2045, secured partnerships like Cytel and Genomind, U.S. manufacturing with Cambrex/Thermo Fisher, and a framework for $60M Europe deal with Molteni, while regaining Nasdaq compliance. Cash is projected to fund operations into H2 2026.

• ·Nasdaq compliance regained on Feb 24, 2026 (notice Feb 23, 2026), matter now closed.
• ·Molteni collaboration framework announced March 3, 2026, subject to definitive agreement.
• ·International patent application for AD04 published Jan 14, 2026 (filed July 2024), potential protection to 2045.
• ·Six-figure milestone payment received from Adovate on May 13, 2025 for Phase 1 trial of ADO-5030.

06-03-2026

Warner Music Group Corp. held its Annual Meeting of Stockholders on March 3, 2026, electing all eleven director nominees with overwhelming support (For votes ranging from 7.55B to 7.63B shares out of approximately 7.64B total votes cast, minimal Against votes under 80M). Stockholders also ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026 with 7.63B For votes and negligible opposition (13.3M Against). No broker non-votes for Proposal 2, indicating strong consensus.

• ·Proxy statement filed with SEC on January 20, 2026.
• ·Proposal 1 broker non-votes: 11,989,796 shares.
• ·Proposal 2: Against 13,299,930 shares; Abstain 33,513 shares.

06-03-2026

Camden National Corporation reported net income of $65.2M for 2025, up 23% YoY from $53.0M in 2024, fueled by the January 2, 2025 acquisition of Northway Financial, Inc., which drove net interest income to $203.3M (+53% YoY) and total assets to $6.97B (+20% YoY). However, non-interest expenses surged 38% YoY to $154.8M due to $9.3M in merger costs, return on average equity declined slightly to 9.96% from 10.36%, and tangible book value per share dipped to $29.69 from $29.91. Adjusted metrics reflected stronger results, including adjusted net income of $74.4M (+39% YoY) and adjusted return on average tangible equity of 17.27%.

• ·Dividends declared per share remained flat at $0.42 quarterly across all quarters in 2025 and 2024.
• ·Adjusted pre-tax, pre-provision income increased to $109.6M in 2025 from $66.2M in 2024.
• ·Non-GAAP efficiency ratio improved to 54.46% in 2025 from 62.05% in 2024.

06-03-2026

Muncy Columbia Financial Corporation (CCFN) has issued its DEF 14A proxy statement for the Annual Meeting of Shareholders on April 23, 2026, at 10:30 a.m. ET, to elect four Class 1 directors for three-year terms and ratify S.R. Snodgrass P.C. as the independent registered public accounting firm for the year ending December 31, 2026. The record date is February 23, 2026, with 3,536,754 shares of common stock outstanding. Proxy materials are available online at www.edocumentview.com/CCFN starting on or about March 13, 2026.

• ·Meeting location: Lightstreet Office of Journey Bank, 1199 Lightstreet Road, Bloomsburg, Pennsylvania 17815.
• ·Board of Directors recommends voting 'FOR' both proposals.
• ·Voting methods: telephone, internet, mail proxy card, or in person.
• ·Plurality vote required for director election; majority of votes cast for auditor ratification.

06-03-2026

IRADIMED CORP reported FY2025 revenue of $83.8M, up 14% YoY from $73.2M in FY2024, driven by strong U.S. growth (+16% to $70.6M) and devices revenue (+16% to $60.0M), including robust increases in MRI IV pumps (+19%) and Ferro Magnetic Detection Systems (+111%). However, international revenue grew modestly at 5% (to $13.3M, down to 16% of total), services revenue declined 4% to $3.9M, and gross margin remained flat at 77%. Operating expenses improved to 45.5% of revenue from 47.0%, boosting income from operations margin to 31.2% from 30.0% and net income margin to 26.8% from 26.3%.

• ·Research and development expenses declined to 3.5% of revenue from 3.9% YoY.
• ·General and administrative expenses improved to 21.2% of revenue from 21.8%.
• ·Sales and marketing expenses decreased to 20.8% of revenue from 21.3%.
• ·Other income, net declined to 2.6% of revenue from 3.2%.

06-03-2026

NVIDIA Corporation's Compensation Committee adopted the Variable Compensation Plan for Fiscal Year 2027 on March 2, 2026, providing eligible executive officers with variable cash payments based on FY2027 revenue performance goals at threshold, base, and stretch levels. CEO Jen-Hsun Huang has a base target award of $4M (200% of FY2027 base salary), while Colette M. Kress, Ajay K. Puri, Debora Shoquist, and Timothy S. Teter each have $1.5M targets (150% of base salary). Eligibility requires continued employment through the payment date.

• ·Fiscal Year 2027 ends January 31, 2027
• ·Performance goals based on FY2027 revenue with threshold, base, and stretch compensation plan levels
• ·Filed as Exhibit 10.1

06-03-2026

Rogers Communications Inc filed its 40-F annual report for FY2025 ended December 31, 2025, detailing operations across Wireless, Cable, and Media segments with year-over-year comparisons to FY2024 and FY2023. The filing discloses the MLSE Transaction on July 1, 2025, involving Maple Leaf Sports & Entertainment Ltd., including assets classified as held for sale, property, plant & equipment, intangibles, and depreciation details. Equity structure includes Class A Voting Shares and Class B Non-Voting Shares, with notes on credit facilities like the Canada Infrastructure Bank Credit Facility due 2052; no specific performance improvements or declines quantified.

• ·Filing date: March 06, 2026
• ·Reporting period: January 1, 2025 to December 31, 2025
• ·Comparative periods: FY2024 (2024-01-01 to 2024-12-31) and FY2023
• ·MLSE Transaction date: July 1, 2025
• ·Disposal groups classified as held for sale: December 2025
• ·Credit facilities include Canada Infrastructure Bank Credit Facility Due 2052, Revolving Credit Facility 1, Accounts Receivable Securitization Program

06-03-2026

Genco Shipping & Trading Ltd filed a DEFA14A on March 6, 2026, disclosing participants in the proxy solicitation for the 2026 Annual Meeting of Shareholders, including independent directors Paramita Das, Kathleen C. Haines, Basil G. Mavroleon, Karin Y. Orsel, Arthur L. Regan, and executives John C. Wobensmith, Peter Allen, Joseph Adamo, Jesper Christensen. The filing urges shareholders to review the upcoming definitive proxy statement on Schedule 14A, white proxy card, and related SEC documents available free on SEC.gov and the company's investor relations site at https://investors.gencoshipping.com/. It references the prior 2025 proxy statement filed April 9, 2025, and multiple Form 4 filings detailing participants' changes in security ownership from May 2025 to February 2026.

• ·Prior proxy statement for 2025 Annual Meeting filed with SEC on April 9, 2025.
• ·Form 4 filings for participants: May 22, 2025; June 3, 2025; August 26, 2025; September 10, 2025; September 15, 2025; November 12, 2025; November 26, 2025; February 18, 2026; February 23, 2026.
• ·Investor contact: Peter Allen, (646) 443-8550; Media contact: Leon Berman, (212) 477-8438, lberman@igbir.com.

06-03-2026

Canadian Pacific Railway Company completed an offering of $600M aggregate principal amount of 4.000% notes due 2029 and $600M aggregate principal amount of 5.500% notes due 2056, for a total of $1.2B, guaranteed by parent Canadian Pacific Kansas City Limited. The notes were issued pursuant to an Eighth Supplemental Indenture dated March 6, 2026, following an Underwriting Agreement dated March 4, 2026, with lead underwriters Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., and SMBC Nikko Securities America, Inc. The offering was registered under a Form F-10 (File No. 333-285353).

• ·Underwriting Agreement dated March 4, 2026
• ·Eighth Supplemental Indenture dated March 6, 2026
• ·Prospectus dated March 6, 2025, supplemented March 4, 2026
• ·Original Indenture dated September 11, 2015
• ·Registration statement on Form F-10 (File No. 333-285353) filed February 27, 2025

06-03-2026

Dyadic International, Inc. entered into an At-The-Market Issuance Sales Agreement with Craig-Hallum Capital Group LLC on March 6, 2026, enabling the sale of up to $4.2M in common stock through at-the-market offerings on Nasdaq. The sales agent will receive up to 3.0% commission on gross sales prices, providing the company flexible access to capital. However, any sales would dilute existing shareholders.

• ·Sales Agreement pursuant to Form S-3 registration statement (File No. 333-273829) effective August 25, 2023.
• ·Either party may suspend or terminate the offering upon notice.
• ·Company to reimburse sales agent for certain expenses and provide indemnification.

06-03-2026

AIM ImmunoTech Inc. (AIMI) filed an 8-K on March 06, 2026, reporting under Items 1.01 (entry into a material definitive agreement), 3.03 (material modifications to rights of security holders), 5.03 (amendments to articles of incorporation or bylaws), 8.01 (other events), and 9.01 (financial statements and exhibits). Exhibit 3.1 was attached, likely containing the amended governing documents. No financial metrics or period-over-period comparisons were disclosed.

• ·Filing items: 1.01, 3.03, 5.03, 8.01, 9.01
• ·Subcategory: Material Agreement Entry
• ·Exhibit: EX-3.1 (likely amended articles of incorporation or bylaws)